

Experiencias de transferencia de tecnología y creación de empresas desde el Sistema Nacional de Salud



**Mission** - Identify, In-License, and Develop innovative biomarkers into **IVD products for cancer** 

## **Oportunity – Building the Lead Cancer Diagnostics Company in Spain**



### **New Company / partnership formed:**

- Founded in June 2010, spin-out of TCD Pharma
- Acquisition of Transbiomed in 2012
- Technology Transfer Agreement with Valld Hebrón Hospital: IP, facilities and researchers in a leading Spanish hospital
- A Stronger Pipeline: 5 products in development
- A Specialized **Team**


#### **In-Licensing Model**

- Defined process, clear established criteria for progression
- Requires:
  - ✓ Clear innovation and supported science
  - ✓ Patent protection
  - ✓ Clear commercial opportunity
- Quantitative evaluation of New Projects across a range of parameters
- In-licensing 1 project per year
- Spain's Research Institutions
  - ✓ High level of scientific excellence and innovation
  - ✓ Currently limited opportunities to realise value of these innovations

## **Pipeline of Products**

Cancer type	Use	Discovery	Clinical Validity	Assay Development	Clinical Utility	Commercialization
Lung (NSCLC)	Prognostic					
	Predictive					
Colon	Prognostic Predictive					
Prostate	Diagnostic (urine)					
	Prognostic (miRNAs)					

**Pipeline** of **5 innovative tests** in development for diagnostic, prognostic and predictive uses, addressing **unmet medical needs** in **lung, colon and prostate** cancer



#### **Conclusion**

# Amadix - Building a lead company in cancer diagnostics, from National Health System of Spain

- ✓ Pipeline of five innovative tests for diagnostics in lung, colon and prostate cancer
- ✓ New Products Address clear unmet medical needs in Oncology
- ✓ Benefits for patients and physicians all around the world
- ✓ High level of scientific excellence and innovation within Spain's Research Institutions





**Thank You for Your Attention**